Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 450

1.

Changes in bone density and turnover after alendronate or estrogen withdrawal.

Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study Group.

Menopause. 2004 Nov-Dec;11(6 Pt 1):622-30.

PMID:
15545790
2.

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.

PMID:
12458987
3.

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.

PMID:
10610644
4.

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd.

Am J Med. 1997 Oct;103(4):291-7.

PMID:
9382121
5.

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.

Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.

Osteoporos Int. 2005 Apr;16(4):372-9. Epub 2005 Jan 15.

PMID:
15654581
6.

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group.

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.

7.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.

N Engl J Med. 1998 Feb 19;338(8):485-92.

8.

Effects of alendronate combined with hormone replacement therapy on osteoporotic postmenopausal Chinese women.

Tseng LN, Sheu WH, Ho ES, Lan HH, Hu CC, Kao CH.

Metabolism. 2006 Jun;55(6):741-7.

PMID:
16713432
9.

BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.

Palomba S, Orio F Jr, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F.

Osteoporos Int. 2005 Aug;16(8):943-52. Epub 2005 Mar 1.

PMID:
15739035
10.

Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.

Ascott-Evans BH, Guanabens N, Kivinen S, Stuckey BG, Magaril CH, Vandormael K, Stych B, Melton ME.

Arch Intern Med. 2003 Apr 14;163(7):789-94.

PMID:
12695269
11.
13.
15.

Comparative effects on bone mineral density of tibolone, transdermal estrogen and oral estrogen/progestogen therapy in postmenopausal women.

Prelevic GM, Bartram C, Wood J, Okolo S, Ginsburg J.

Gynecol Endocrinol. 1996 Dec;10(6):413-20.

PMID:
9032569
16.

HRT and exercise: effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women.

Heikkinen J, Kyllönen E, Kurttila-Matero E, Wilén-Rosenqvist G, Lankinen KS, Rita H, Väänänen HK.

Maturitas. 1997 Mar;26(2):139-49.

PMID:
9089564
17.
18.

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al.

Am J Med. 1995 Aug;99(2):144-52.

PMID:
7625419
19.

Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.

Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen C.

Osteoporos Int. 2004 Feb;15(2):168-74. Epub 2003 Nov 25.

PMID:
14647880
20.

The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.

Arrenbrecht S, Caubel P, Garnero P, Felsenberg D.

Maturitas. 2004 Jul 15;48(3):197-207.

PMID:
15207885

Supplemental Content

Support Center